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ABSTRACT
There have been substantial progresses in the technology of cardiac implantable electric devices
(CIEDs) during the past decades. One of the progresses is represented by the development of a
hemodynamic sensor embedded at the tip of a pacing lead that measures myocardial contractility
by the analysis of myocardial mechanical vibrations occurring during the cardiac cycle. This
sensor, providing continuous hemodynamic monitoring, could play an important role in clinical
practice because of several clinical applications in CIEDs recipients. The objectives of this work
are to report how this sensor operates and to review the main findings about its clinical
applications.
Keywords: hemodynamic sensor, peak endocardial acceleration, myocardial contractility,
cardiac implantable devices.
1. INTRODUCTION
Cardiac implantable electric devices, pacemakers (PMs), implantable cardioverter-
defibrillators (ICDs) and devices for cardiac resynchronization therapy (CRT),
represent today the “well-proven efficacious” tools in the treatment of cardiac
arrhythmias and heart failure (HF) [1]. Over time, a progressive improvement of the
available diagnostic and therapeutic algorithms has been observed, mainly related to
the detection of cardiac arrhythmias, management of pacing/sensing thresholds,
reduction of unnecessary ventricular pacing, prevention of atrial tachyarrhythmias
recurrence, development of rate responsive pacing and rate adaptive atrioventricular
(AV) delay functions, allowing a better management of patients. A reliable
continuous hemodynamic information could improve the outcome of patients by a)
continuously optimizing the device settings, b) preventing acute recurrences of heart
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failure, and c) improving clinical decision-making processes [2–4]. One of the major
and most recent innovations is represented by the development of a hemodynamic
sensor incorporated at the tip of a pacing lead. This sensor, measuring myocardial
vibrations during the cardiac cycle by an endocardial accelerometer suitable for the
lead, has been developed for a direct measurement of myocardial contractility
[5–10].
The objectives of this work are to report how this endocardial acceleration
technology works and to review the main clinical findings about its current use.
2. PRINCIPLE OF ENDOCARDIAL ACCELERATION TECHNOLOGY
2.1. Myocardial Contractility
The contractile state of the heart is currently determined invasively by a direct recording
of the maximum rate of rise of the left ventricular pressure (LV dP/dt max) [11, 12]. LV
dP/dt max is universally accepted as a good index to assess acute changes in
contractility and it is currently considered the gold-standard for the assessment of the
contractile force [12].
2.2. Peak Endocardial Acceleration (PEA) Signal as an Index of Myocardial
Contractility
The hemodynamic endocardial acceleration (EA) sensor, embedded at the tip of an
implantable pacing lead, is a detector of the acceleration of the endocardial wall of the
left ventricle. It has been defined as a “Microphone Inside the Heart” because it records
and amplifies myocardial vibrations during the cardiac cycle transforming them into an
electric signal that is processed and converted into a peak endocardial acceleration’s
signal (PEA signal).
Preliminary studies have shown that changes at the peak of these myocardial
vibrations occurring during isovolumic systole (peak endocardial acceleration I, PEA-I)
are closely related to changes in LV dP/dt max [5, 7, 8, 10]. Thus, these studies have
identified the peak of endocardial acceleration (PEA) as an index of myocardial
contractility.
The peak of the myocardial vibrations can be recorded also during the isovolumic
relaxation phase of the cardiac cycle (peak endocardial acceleration II, PEA-II).
Preliminary studies have shown that PEA-II closely correlates with the min LV dP/dt
value [7, 8]. Thus, PEA components’ measurement, corresponding to the extent of
cardiac cycle’s isovolumic contraction and relaxation, allows monitoring of both
systolic and diastolic function of the left ventricle.
Furthermore, Tassin et al. reported a close correlation between amplitude/timing of
PEA-I and PEA-II components and amplitude/timing of first and second heart sounds,
as detected by standard external phonocardiographic (PCG) recordings, supporting that
PEA and heart sounds are manifestations of the same phenomena [13]. In fact, it is well
known that heart sounds generation is dominated by myocardial vibrations during both
isovolumic contraction and relaxation, as well as by other factors including blood
acceleration/deceleration within the ventricles and the movements of valves leaflets.
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2.3. Endocardial Acceleration Sensor
Myocardial mechanical vibrations can be recorded by an endocardial accelerometer
(EA sensor) equipped with pass-band filters tuned to reject the spurious components
derived from body movements and external interferences. The pass-band filter has been
selected as a result of the initial in-vivo research around the endocardial acceleration
signal. The filter is a numeric pass-band filter with two first-order corner frequencies of
10 and 128 Hz. The piezoceramic bender and the electronics within the sensor act both
by filtering the acceleration components outside the range of 10 Hz to 128 Hz. There is
no dynamic or adaptive tuning of the filtering, hence there is no tuning algorithm.
Myocardial vibrations can be effectively detected regardless of the endocardial position
of the sensor [6, 7, 10]. Independent from the recording site, the endocardial
acceleration signal can be equally detected and processed [6, 7, 10]. The correlation
between the peak endocardial acceleration signal and the human cardiac contractility
expressed in terms of LV dP/dt max exists independent of the recording site by the
SonR sensor, whether it is the apex of the right ventricle, the coronary sinus or the right
atrial appendage [6]. This signal provides a reliable estimation of the global cardiac
contractility rather than a measure of the regional contractility or local kinetics [6, 7].
The interior of the sensor consists of the following three basic components (Figure 1a):
1) A “seismic mass and microspring” system, to amplify the mechanical movements due
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Figure 1. Endocardial accelerometer (EA) sensor. (a) Interior components. (b)
Exterior components: a titanium can (left) that coils up the inner sensor
components, and is covered by a silicone sheath (right).
to myocardial vibrations and to improve the resistance to mechanical shocks. The
function of the microspring is to provide a mechanical dampening to decouple the mass
from the bender in case of shock. This arrangement ensures adequate resilience of the
sensor to mechanical shocks, such as those that could occur during handling of the lead.
2) A “piezoceramic bender”, to transduce flexural stresses into electric (voltage) signal.
This voltage signal derived from the sensor to identify the PEA-I component does not
interfere at all either with sensing signals or with delivered therapy. In order to detect the
PEA-I component, every time an R-wave is detected by the ventricular sensing channel,
the implanted device opens a “sensor detection window”, just after the R-wave, for a
specific limited time interval. This allows the system to completely uncouple the
detection of the acceleration components from the sensing and pacing functions. The
device applies commonly used blanking techniques to decouple the sensor and sensing
signals. In fact, when a “sensor detection window” is opened after the R wave, the atrial
pace/sense dipole is in any case in refractory conditions (a post-ventricular refractory
period is triggered by any ventricular paced or sensed event, in order to avoid atrial
oversensing due to the ventricular activation). This sensing control system does not
impact the performance of atrial arrhythmias monitoring. 3) An “epoxy clamp”, defining
the free vibrating part of the bender. The “sensitivity of the sensor” is determined by the
physical arrangement of its components. The seismic mass participates, together with 
the piezoceramic bender transducer and the overall structure of the assembly, to obtain
the required sensitivity. The electronic circuit inside the sensor acts as a “buffering
circuit” in order to ensure proper transmission of the signal to the device without
applying any voltage gain to the signal generated by the transducer.
The assembly of the inner portion of the sensor is completed by connecting the basic
components to the electronics (first-line processing and filtering of the voltage signal),
which is in turn connected to a feed-through element, aiming to maintain full
hermeticity and to ensure electric continuity with lead conductors. The exterior of the
sensor (Figure 1b) consists of a rigid titanium can coiling-up the inner assembly to
protect the basic structures of the EA sensor, which is in turn protected by an insulating
silicone sheath.
2.4. EA Signal Acquisition and Processing
The EA signal is generated by the vibrations of the cardiac structures during the cardiac
cycle. These vibrations propagate through the cardiac walls. When the vibration arrives
in proximity of the sensor-carrier lead tip, the vibration itself produces a microscopic
oscillation of the seismic mass, which in turn produces a flexural stress on the
piezoceramic bender. The piezoceramic bender transforms the oscillation into a voltage
signal. The signal is then sent to the circuits of the implanted device, which are capable
of the following: 1) reading the real-time filtered signal, and 2) extracting the peak-to-
peak amplitudes of the PEA-I components.
2.5. Technology of the Lead
The described EA sensor has been designed to be sealed into the tip of a lead for
endocardial permanent pacing/sensing function, making this technology suitable for
clinical applications associated with implantation of cardiac implantable electric
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devices (CIEDs) with or without resynchronization capability. The advantages of an
endocardial sensor installed in the distal portion of a pacing lead are the following: 
1) a permanent implantation in the right heart with continuous monitoring of the EA
signal that is an index of myocardial contractility [7]; 2) no need for additional leads as
pressure sensor leads or conductance catheters to achieve a hemodynamic monitoring.
The main limitation of this EA sensor lead, that is similar to a “standard lead” in terms
of sensing, pacing functions and handling and physical characteristics, seems to be
related to the fact that it works only in combination with a dedicated device, equipped
with a specific atrial port designed to receive a tripolar connection of the lead. This
tripolar connector is based on a design of an IS-1 BIP connection standard.
The proximal part of the EA sensor lead is depicted in Figure 2. One of the
hardware poles is common to the two functions (managed via software by the CIED).
The sensor is electrically connected between the distal electrode (tip) line and the
dedicated (third pole) sensor line. The distal electrode line is the sensor reference
(ground) pole, while the sensor line is the active pole, where the signal is transmitted.
During the sensor powering periods, the current flows on the distal and sensor lines
and through the sensor, activating the sensor and allowing the device to sample the EA.
No current is delivered to the heart because no current path exists outside the lead
during the sensor activation period. Of note, the lead portion just outside the header of
the device has been designed with an inner “transition-spring” mechanical component;
in the connector portion, the transition spring has the function to allow the lead to bend
while protecting the conductors from being overstressed and providing pushability for
the connection. In the distal end, the stiffness is reduced to improve handling and
positioning in the atrium. A dual-layer silicone and polyurethane insulation ensures
consistent mechanical protection and electrical insulation to the lead conductors. The
electric continuity between the CIED and the EA sensor allows a bidirectional flow for
the following functions: 1) Power supply from device batteries to sensor electronics
(controlled injection of current pulses). The frequency of the transmission is 512 Hz.
The impact on the lifetime of the device is estimated to be less than or equal to 0.4
years. 2) EA signal transmission from sensor electronics to the device (for further
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Figure 2. Proximal part of the EA sensor lead with tripolar connection: distal bipole
for pacing/sensing function (based on a design of an IS-1 BIP connection
standard) and dipole for EA signal transmission to the device.
processing). The EA signal has significant information in the range between about 10
and 120 Hz, with a peak in the 40–70 Hz range, and has essentially no component
above 250 Hz. The peak-to-peak amplitude of the systolic component ranges between
0.2 g (1 g = 9.81 m/s2) and 2 g, depending on several factors related to cardiac
contractility, atrioventricular (AV) and interventricular (VV) timings, and more
generally to the hemodynamic state of the heart. The signal of the sensor is sampled at
512 Hz by the device and digitized. A numeric band-shaping filtering (10–128 Hz) is
subsequently applied to the signal, providing the rejection of spurious signal
components from potential sources of interference. The appropriate filtering has been
selected after extensive study of the EA signal, based on wide-band (1 – 1000 Hz)
recording of the accelerometer signals in several different conditions. Beat to beat
variability of the signal is largely dominated by the cardiac variability, which is greater
for heart failure patients than for other patients with preserved myocardial function. In
the currently available device, the algorithm robustness is ensured by averaging the
measured signal over a few consecutive cycles (typically 4 to 7). The initial findings
have shown that sensor signal is not interfered by patient’s voice, cough, pulmonary
rales. The heart is indeed almost “floating” inside the chest, and the propagation of
external vibrations is significantly attenuated. Low-frequency phenomena, such as
components related to the respiration activity, can be also cut-off. For instance, the
atrial tissue depolarization in atrial fibrillation condition - considered to be a spurious
component to the sensor - very rarely exceeds 10 Hz (corresponding to 600 bpm); thus
this component is effectively cut-off. As the technology evolves, in terms of
miniaturization and improvement of the sensitivity of the sensor, several lead models
equipped with EA sensor have been released, featuring different fixation mechanisms
to the endocardial walls (tined or screw-in) and a progressive downsizing of the lead
body. Recently, the target chamber for sensor implantation switched from the right
ventricle (RV) to the right atrium (RA). The choice to move the sensor placement from
the right ventricle to the right atrium has nothing to do with the EA technology itself.
The encapsulation of a micro-accelerometer sensor inside the tip of the right
ventricular pacing lead represents a constraint because of ongoing technological
progress and changes in the implantation indications [9]. In particular, patients
suffering from heart failure are regular candidates for the implantation of a CRT-D
system (cardiac resynchronization therapy with pacemaker/defibrillator function),
which requires an RV lead designed to pace, sense and defibrillate with a complex
array of coils and electrodes [9]. Consequently, a right atrial lead equipped with PEA
sensor could be used for hemodynamic sensing of the ventricular contraction/
relaxation phases of the cardiac cycle, without impending the development of the
ventricular leads [9, 10]. This is to avoid the inclusion of the EA sensor at the tip of an
RV lead, which is already jammed with defibrillation coils and multiple conductors.
Moreover, Bordachar et al. demonstrated that a sensor placed in the atrium offers the
major advantage of sensing a signal coincident with atrial contraction [9]. This might
allow, in future applications, inclusion of this component of PEA in various
algorithms, such as that for the automatic control of atrial pacing capture or AV delay
optimization, with a view, among other objectives, to sharpen the tachyarrhythmia
discrimination by implanted devices.
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3. LITERATURE REVIEW
3.1. Rate-Responsive Pacing Function
The close relationship between contractility and heart rate has been employed to
develop a closed-loop algorithm capable of driving rate-response (RR) in pacemakers
equipped with EA sensor. This sensor, measuring cardiac contractility, bases its rate
response on myocardial contractility, a measurement physiologically modulated by the
baroreceptors, derived directly from the heart, which changes with heart rate during
exercise, although less prominently [14]. Two studies have shown that changes in PEA
signal recorded by EA sensor are closely correlated with sinus node rate during exercise
and pharmacological interventions [14, 15]. In patients with normal chronotropic
function, Clementy et al. first reported that PEA signal was linearly correlated with
sinus rates during cycloergometer effort test [15]. In patients with chronotropic
incompetence implanted with PEA-based PM, the variations in PEA-driven paced heart
rate were closely correlated with those observed in controls with normal sinus rhythm
[14]. Furthermore, a robust correlation was found between PEA variations and
calculated energy cost of exercise (metabolic equivalent, MET) during the steps of
standardized protocols (bycicle or Bruce) [16].
3.2. Pacing for Neurally-Mediated Syncope
The therapeutic role of permanent dual chamber pacing in patients with malignant
neurally-mediated syncope (NMS) refractory to pharmacological therapy remains
controversial. This is mostly due to the fact that standard pacing systems cannot detect
the hypotension usually preceding bradycardia when an NMS occurs. Previous studies
postulated that a reflex increase in sympathetic activity results in vigorous myocardial
contractions before an NMS [17]. As a consequence, the increased inotropic activity, as
detected by EA sensor during head-up tilt test, was hypothesized to allow an early
intervention by pacing to avoid NMS event [18, 19]. Deharo et al. evaluated the rate of
symptomatic NMS recurrences and quality of life (QoL) score in a 6-month period
preceding the PM implantation and after conventional DDI pacing (asynchronous
atrioventricular pacing) or DDDR pacing (rate-responsive synchronous atrioventricular
pacing) driven by contractility, in a randomized cross-over design. Contractility-driven
DDDR pacing induced a higher reduction of symptomatic NMS recurrence, although
QoL scores were similar in the two pacing modes [20].
3.3. AV Delay Optimization in DDD Pacing (Synchronous Atrioventricular Pacing)
A dedicated algorithm based on PEA signal was developed to identify the optimal AV
delay (AVD) value in patients affected by complete AV-block and indication for DDD
pacing [21]. The EA signal rises from the combination of two effects: the myocardial
contractility and the noise due to the movements of the mitral valve. In the condition of
a very short AV delay value, the effect of mitral valve becomes predominant (“big
noise” generated by the truncation of the A-wave). In the condition of a long AV delay
value, the effect of mitral valve becomes minor (“small noise”). The optimal AV delay
corresponds to the inflection point of the EA signal curve. Significant reports showed
that the optimal AVD identified by the EA algorithm, both at rest and under effort, was
correlated with that identified by the gold-standard echocardiographic method [21, 22].
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3.4. Cardiac Resynchronization Therapy (CRT) Optimization
Cardiac resynchronization has been demonstrated to be an efficient therapy for patients
with systolic advanced HF and dyssynchrony; however, up to 40% of patients do not
show improvement in left ventricular performance or clinical symptoms after CRT [23].
Device optimization is expected to lower the proportion of non-responders, and
continuous changes of the programmed AV and VV intervals may be required [24]. A
third-generation algorithm based on PEA signal was conceived, aiming at a continuous
automatic AV and VV delays optimization in CRT devices. This algorithm determines
first the optimal VV synchrony, then the optimal AV synchrony under different
conditions (atrial sensing and pacing, patient at rest or under effort), globally lasting a
few minutes. VV delay optimization is carried out by night, with the patient at rest. For
each specific VV delay configuration, the algorithm forces an AV delay scanning in
DDD pacing mode (over a range of AV delay compatible with full ventricular capture
with the max value of the range defined by an AV delay shorter than the spontaneous
AV) and measures the EA values accordingly. The resulting “EA versus AV delay”
curves are compared by measuring the EA area below the curves. The value of the EA
area is an expression of the overall contractility related to a specific VV delay under
different filling conditions. The optimal VV delay value corresponds to the highest
value of the EA area. The therapeutic effect of an optimal VV delay was demonstrated
to consist of a positive hemodynamic response to CRT defined as an increase by 10%
in the invasive LV dP/dt max [25]. Once the optimal VV delay is determined and
reprogrammed, the device looks for the optimal AV delay with the patient still at rest.
As the variable electromechanical latencies and the inter and intra atrial delays may
significantly affect filling performance, the algorithm identifies the optimal AV delay in
both atrial sensing (DDD 50 bpm to favour sinus rhythm) and atrial pacing conditions
(DDD 70 bpm to overdrive sinus rhythm) [4, 21, 23, 26]. The optimal AV delay always
corresponds to the inflection point of the EA versus AV delay value curve [26]. The
filling performance may also significantly change with heart rate, due to physical
exercise. During the day the algorithm checks if the patient’s heart rate exceeds a
programmable target value for testing (90 bpm to 110 bpm). In this case the procedure
of AV delay optimization is carried out at the testing heart rate to identify the optimal
AV delay under effort. Every week, the algorithm iterates the full procedure to identify
and reprogram the best device settings to assure optimal VV synchrony and AV
synchrony in any patient condition.
The “CLEAR” multicenter pilot study [27] prospectively assessed the clinical
benefit of automatic CRT optimization by EA hemodynamic sensor. The automatic
CRT optimization (“PEA” group) was compared with the Standard-of-Care clinical
criteria (“SoC” group) of the participating centres. The primary endpoint of the study
was the Packer’s Clinical Combined Criterion (all-cause mortality, HF-events, NYHA
functional class, QoL score) evaluated at 1-year follow-up, focusing on the rate of
clinical response (i.e patients who significantly improved according to Packer’s
endpoint). The study was conducted between 2005 and 2009 years at 51 Centres in 8
European Countries. The implanted system consisted of a CRT-PM with an EA
MiniBest® (Sorin Biomedica, Saluggia, Italy) sensor lead in the right ventricle. The
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difference in the primary endpoint between the two groups was highly significant: 76%
PEA vs. 62% SoC (p = 0.0285) [27].
A new trial is currently in progress to further confirm the clinical benefit of
automatic CRT optimization by EA sensor [28]. This trial includes HF patients of any
etiology, eligible for CRT-ICD, in sinus rhythm and NYHA functional class III and IV,
with LVEF < 35% and QRS > 120 ms. The objective of this study is to compare in a
randomized experimental design (2:1 ratio) patients with ambulatory CRT optimization
based on weekly re-assessment of the hemodynamic performance by EA sensor and
patients optimized only once before hospital-discharge (by using standardized
echocardiographic method: longest LV filling time without A-wave truncation and
maximum Aortic-VTI). The same endpoint of the pilot CLEAR study (Packer’s
criterion) is used, imposing a double-blinded assessment of the rate of clinical response
at 1-year follow-up. The target chamber for the proposed EA sensor, named SonR®, is
the right atrium (“SonRtip” screw-in lead, SORIN CRM srl, Saluggia, Italy).
4. DISCUSSION
We have reviewed the main clinical findings about the EA technology. Preliminary
studies have demonstrated that the measurement of myocardial contractility by an
accelerometer sensor embedded at the tip of an implantable pacing lead is feasible 
[5-10] and it may have wide promising clinical applications [14–22, 27], as summarized
in Table 1. Among them, the potential contributions of EA sensor timings in the
detection of cardiac mechanical events and in the precise measurement of systolic and
diastolic periods, suggest that this sensor could be useful in the monitoring of cardiac
function and adaptative optimization of CRT [29].
At present, the development of CRT devices that are able to find the optimal
setting automatically for both AV and VV intervals, and to reset it regularly at rest and
during exercise represents an important field of research [30]. The inaccurate
programming of the AV delay, VV delay, or both has proven to be a weighty cause of
non-response to CRT [4, 30]. Although echocardiography is currently the most
reliable method to optimize AV and VV intervals, this time-consuming, operator-
dependent task is not performed systematically and, when performed, is limited to
conditions of rest in a supine position [4, 30]. Several alternative non-
echocardiographic methods have been proposed to optimize AV and VV intervals
such as invasive measurement of the LV dP/dt max, acoustic cardiography,
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Table 1. Clinical Applications of EA technology in CIEDs recipients
EA sensor
1) Rate-Responsive Pacing Function
2) Pacing for Neurally-Mediated Syncope
3) AV Delay Optimization in DDD Pacing
4) CRT Optimization
impedance cardiography and methods based on automated algorithms such as
QuickOpt method and SmartDelay algorithm [30]. These algorithms use intracardiac
electrograms to automatically optimize AV and VV delays in biventricular pacing [4,
30]. The FREEDOM and SMART-AV studies [31, 32], that evaluated prospectively
the benefit of a frequent optimization of the AV and VV intervals using the QuickOpt
method and the SmartDelay algorithm respectively, did not report a significant
contribution to further improve responsiveness to CRT compared with the empirical
setting or the echo-doppler iterative method [4]. The automated algorithms are
operator-independent and time-saving CRT optimization tools. Their lack of benefit
may be due to the rest condition and to the low frequency of the AV and VV intervals
optimization. Moreover, Porciani et al. have shown that automatic algorithms such as
QuickOpt may fail to identify the best AV and VV intervals, since in patients with
severe heart failure the electrical activation times do not always coincide with the
times of mechanical activation [33]. While previous automatic algorithms did not
demonstrate any beneficial effect, the automatic PEA method, based on the
mechanical acceleration of the heart has been shown to be closely consistent with
the cardiac ultrasound in the timings of aortic and mitral valve closures and in the
estimation of systolic and diastolic intervals durations [29]. The benefit of this
method could be due to the fact that it allows a weekly automatic optimization of the
AV and VV intervals at rest and also during exercise. The CLEAR study
demonstrated clinical benefits of the CRT achieved by the PEA configuration
compared with CRT optimized by standard clinical procedure [27].
5. CONCLUSIONS
The EA technology, embedded at the tip of a standard permanent lead for cardiac
pacing/sensing function has opened a new era in cardiac pacing allowing measurement
of the myocardial contractility. This technology is employed in driving rate-response
pacing function, preventing and treating neurally mediated syncope, and optimizing
automatically AV and VV delays in CRT.
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